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Objectives: To estimate the incremental cost-utility ratio (ICUR) for the use of a 
continuous infusion pump with integrated monitoring (SAP) compared with the 
application of multiple daily injections (MDI) in adult (> 15 year-old) patients with 
type 1 diabetes mellitus (DM1) in Colombia. MethOds: We designed an annual 
cycle Markov model, with transition probabilities obtained from a systematic review 
of the literature. Outcomes included in the search were ketoacidosis, severe hypogly-
cemia, microvascular complications (retinopathy, nephropathy, neuropathy), quality 
of life (expressed in quality-adjusted life years, QALYs, and obtained from Tufts 
database), as well as mortality. Other features of the model were: discount rate 3.5% 
for costs and QALYs, third party payer perspective (only direct medical costs), and 
a lifespan time horizon (up to 55 years). Threshold used was three times per capita 
gross domestic product (GDP), equivalent to € 17,547. Costs were estimated in 2014 
Colombian pesos (1 euro = 2,660 COP), from base case scenarios (built by expert 
panels) and official tariff manuals. Univariate and probabilistic sensitivity analy-
sis were performed. Results: For the average patient, continuous infusion pump 
has a total expected cost of € 199,296, and generates 16.40 QALYs, while multiple 
daily injections would cost € 104737, and generate 14.48 QALYs (ICER € 49,302 per 
additional QALY gained). Sensitivity analysis shows that the only critical variable 
is the annual cost of continuous infusion pump treatment, which would have to 
be reduced by 40% to reach the cost-utility threshold. cOnclusiOns: Under the 
assumptions of the model, treatment with continuous infusion pumps would not 
be cost-effective for the average adult DM1 patient in Colombia. Further analysis 
would be required, addressed to certain selected subgroups of patients.
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Objectives: To evaluate cost-utility of HAL assisted TURB in comparison to TURB 
with WLC alone in patients with previously diagnosed NIMBC in Poland. MethOds: 
Analysis was performed in 2014, from a public payer’s perspective with a lifetime hori-
zon. “HAL cost-effectiveness model in non-muscle invasive bladder cancer (NIMBC)” 
by Pharmerit Ltd. was adapted to Polish settings. The model consists of two parts: 
a short-term decision tree to assess outcomes of TURB and a Markov cohort model 
developed in order to examine long-term outcomes. Clinical efficacy of HAL was based 
on a systematic review of randomized clinical trials. Data concerning course of disease 
and standard of care in Poland were based on available observational studies, expert 
opinion and guidelines. Difference in utilization of resources between HAL assisted 
TURB and TURB with WLC alone was estimated on the basis of expert survey. Unit 
costs of drugs and medical procedures were based on Ministry of Health (MoH) and 
National Health Fund tariffs. Costs and effects were discounted at rates of 5% and 
3.5%, respectively. The cost-effectiveness threshold was set to 119,577 PLN accord-
ing to MoH requirements. Probabilistic sensitivity analyses (PSA) were conducted 
to assess the probability that HAL is cost-effective in Polish settings. Results: The 
difference in health outcomes between HAL assisted TURB and TURB with WLC alone 
was 0.034 QALY in favor of HAL. HAL assisted TURB was approximately 172 PLN more 
expensive than TURB with WLC alone. Incremental cost per QALY equaled 4,997 PLN. 
PSA indicated that HAL was cost-effective with probability of 95.9% and dominant 
with probability of 44.6%. cOnclusiOns: Use of HAL to assist TURB is cost-effective 
in Poland when compared with TURB with WLC alone.
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Objectives: To assess the cost-effectiveness and to project the clinical ben-
efits of sensor augmented pump (SAP) compared to continuous subcutane-
ous insulin infusion therapy alone (CSII), in type 1 diabetic patients (T1D), in 
Netherlands. MethOds: The Core Diabetes Model was used to project the incidence 
of diabetes-related complications, based on a meta-analysis from Pickup comparing 
SAP vs CSII. In the Pickup meta-analysis, 70% sensor usage in a population with 
baseline HbA1c of 8.0% led to a reduction of -0.42% versus -0.10% HbA1c, for SAP and 
CSII respectively. The simulated population had a mean age of 27 years with a mean 
diabetes duration of 13 years. The quality of life was adjusted for a reduced fear of 
hypoglycaemic event in the SAP arm. A discount rate of 4% and 1.5% for respec-
tively economic and clinical outcomes was applied. Several sensitivity analysis 
were conducted on key parameters. Results: The incremental cost-effectiveness 
ratio (ICER) was 22,335 € per Quality Adjusted Life Year gained (QALY) based on 
a societal perspective. The improvement in discounted QALY was 1.768 years in 
favor of SAP. SAP additional related costs were partially offset by the savings due to 
the reduction in diabetes long-term complications and lower frequency of SMBG. 
Reduction in the incidence (%) and delay of onset of diabetes complications (years) 
were achieved with SAP compared to CSII alone, such as neuropathy (13% 1.3 years), 
first ulcer (5% 1.19 years) and stroke (4% 0.81 years). The acceptability curve showed 
that the likelihood to be cost-effective at a willingness to pay of 80,000 € /QALY 
was 100%. cOnclusiOns: These results indicate that accordingly to commonly 
accepted threshold SAP compared to CSII alone can be considered as very good 
value for money in the Dutch setting. Extensive sensitivity analysis on key drivers 
confirmed the robustness of results.
follow-up this may not always be the most cost-effective alternative. In fact, eco-
nomic evaluations have shown that incremental cost-effectiveness ratios (ICERs) 
of CRT-D may be substantially higher than for comparators. A recent study dem-
onstrated that certain biomarkers may in fact reflect the increased susceptibility 
to SCD in patients with HF and this may further contribute to increase cost-effec-
tiveness of the CRT-D interventions. The objective of this study was to explore the 
cost–effectiveness of a hypothetical perfect biomarker for risk assessment and sub-
sequent treatment decision in implanting CRT-Ds in heart failure patients who com-
ply with the current clinical guidelines and assess the societal value (headroom) of 
such test. MethOds: The study uses a decision analytical model. Results: The use 
of a hypothetical perfect biomarker for implanting CRT-Ds in heart failure patients is 
a cost-effective healthcare intervention. The headroom (societal willingness to pay 
multiplied by incremental quality-adjusted life years) available for the hypothetical 
perfect biomarker ranged from € 1,530 to € 6,120 depending on the willingness to pay 
threshold. cOnclusiOns: The use of a hypothetical perfect biomarker for implant-
ing CRT-D is cost effective. Substantial cost can be saved by a better identification of 
patients with high-risk for SCD and for whom implantation of CRT-Ds reduces risks 
of death. However, further research of risk stratifying biomarkers test accuracy is 
needed to support and strengthen the results of this modeling study.
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Objectives: To investigate the long-term cost-effectiveness of initiating transanal 
irrigation* (TAI) as second-line management in patients with neurogenic bowel 
dysfunction (NBD) who have failed first-line standard bowel care (SBC). MethOds: 
A deterministic Markov decision model was developed to project the lifetime health 
economic outcomes, including quality-adjusted life expectancy (QALE), episodes 
of faecal incontinence (FI), urinary tract infections (UTIs), and stoma surgery when 
using TAI relative to continuing SBC. Patients could transition from TAI to (a) another 
round of first-line SBC, (b) third-line surgeries (sacral nerve stimulator, sacral ante-
rior root stimulator, antegrade continence enema) or (c) stoma as the absorbing 
state. Transition probabilities and QALE estimates were based on real-world data 
collected at three clinics in UK from 2007-2014, in NBD patients due to spinal cord 
injury (SCI), multiple sclerosis, spina bifida, and cauda equina syndrome. Transition 
probabilities for failed SBC patients were collected from 2000-2007 prior to avail-
ability of TAI. Projected life-expectancy was based on published SCI population data. 
One-way sensitivity analyses were applied. Results: The model predicts that a SCI 
patient diagnosed aged 30, with a life expectancy of 37 years using TAI, will experi-
ence a 36.1% reduction in FI, 28.7% reduction in UTIs, a 35.4% reduction in stoma 
surgery and improvement of 0.40 years of QALE, compared with patients continuing 
SBC. Lifetime cost-savings of £41,620 per patient was estimated for TAI versus SBC 
in a SCI patient, primarily due to avoided hospitalizations and stoma surgeries. 
Incremental cost can differ due to altered life-expectancy (and age of diagnosis) in 
the patient cohort. One-way sensitivity analyses indicated that the model was most 
sensitive to variation in utilities on TAI and SBC treatment. cOnclusiOns: TAI is a 
cost-saving treatment strategy reducing risk of stoma surgery and improving QALE 
for NBD patients who have failed SBC. *Peristeen (Coloplast A/S).
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Objectives: To assess the reduction of complications and costs with continu-
ous subcutaneous insulin infusion (CSII) versus multiple daily injections (MDI) in 
uncontrolled type 2 diabetic patients (T2D) in the UK. MethOds: The incidence of 
diabetes-related complications was calculated based on the Core Diabetes Model. 
The population characteristics, the reduction of HbA1c, and insulin dose were based 
on the Opt2mise study (Reznik et al., Lancet 2014) (mean age 56 years (SD 9.6); mean 
diabetes duration 15 years (SD 0.75)). For a baseline HbA1c of 9.0%, the reduction in 
HbA1c was -1.1 % versus -0.4%, respectively, for CSII vs MDI. Costs were UK-specific 
and expressed in £2014. Results: The diabetes-related complications were reduced 
with CSII. At 5 years, the incidence reduction in complications associated with eye dis-
eases, renal diseases, ulcer/amputation and cardiovascular diseases were -24%, -26%, 
-19% and -10%, respectively, in favour of CSII. This equates to a cost reduction of 12% 
over 5 years per patient. End stage renal disease was delayed by 1 year, neuropathy by 
1.08 years and amputation by 0.87 year, myocardial infarction and stroke by 0.81 and 
0.71 year respectively. Insulin dose was reduced for patients on CSII from 122.1 IU to 
96.5 IU per day with a cost saving of £2,169 per patient over 5 years. cOnclusiOns: 
Improvements in HbA1c with a decrease in overall insulin requirements observed 
with CSII versus MDI, may offer important reductions in diabetes-related complica-
tions and associated costs in a UK setting for uncontrolled T2DM patients.
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spirometry, BDR and FeNO testing. Where diagnostic uncertainty remained, indi-
viduals would then undergo PEF and finally MCT testing. This strategy dominated 
other strategies that did not utilise MCT, producing higher health outcomes at a 
lower cost to the health service. Two strategies that made more individuals undergo 
MCT were not cost-effective at the threshold with incremental cost-effectiveness 
ratios of £20,276 and £32,565 per/QALY respectively. Although assumptions were 
made relating to conditional dependence and the consequences of false diagnoses, 
the model’s results were found to be robust to significant changes in these and 
other uncertain parameters. cOnclusiOns: These findings highlight the need for 
thorough objective testing for diagnosing asthma as doing so has the potential to 
improve health outcomes whilst reducing costs to the health service.
PMD97
risk faCtors for DeveloPing DiaBetes as a DeterMinant of tHe Cost-
effeCtiveness of Using Coronary CalCiUM sCore to gUiDe PriMary 
Prevention WitH statins
Silva Miguel L1, Ferreira AM2
1CISEP (Research Centre on the Portuguese Economy), Lisbon, Portugal, 2Hospital de Santa Cruz 
and Hospital da Luz, Carnaxide and Lisbon, Portugal
Objectives: The determination of coronary calcium score allows to identify indi-
viduals for which primary prevention with statins may be unnecessary. In this 
study it is shown that the presence of risk factors for developing diabetes interacts 
with the benefits of this identification. MethOds: A Markov model was used to 
estimate the evolution of two cohorts with elevated C-reactive protein and low 
LDL cholesterol: one without risk factors for developing diabetes and another with 
those risk factors. The progression of both cohorts was simulated assuming four 
alternative strategies: “no treatment”, “treat if score> 100”, “treat if score> 0” and 
“treat all”. Results: For individuals without risk factors for diabetes, the “treat all” 
strategy is the most expensive but allows to achieve better clinical outcomes, with a 
cost per QALY of 24,164€ vs. the strategy “treat if score> 0”. For those with risk factors 
for diabetes, the strategy “treat all” remains the most expensive, but the decrease in 
coronary events does not compensate the increase in diabetes incidence, whereby 
the strategy “treat all” is dominated by “treat if score> 0”. The cost per QALY of this 
latter strategy in comparison to “treat if score> 100” is 36,034€ . Deterministic and 
probabilistic sensitivity analysis show that results are robust. cOnclusiOns: The 
presence of risk factors for diabetes affects the cost-effectiveness of using coronary 
calcium score as a guide to implement primary prevention in this population.
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Objectives: Each year approximately 900,000 new cases of hematological malig-
nancies are diagnosed globally. Diagnosis is comprised of multiple modalities, 
including flow cytometry. Current laboratory developed testing (LDT) for flow cytom-
etry is non-standardized and error prone. Insufficient research has been published 
evaluating the cost and errors in this space. Manual work, including steps such as 
antibody selection, compensation, and pipetting have been identified as potential 
sources of error in flow cytometry. The aim of this study is to quantify the time 
and associated economic impact of manual work in a flow cytometry process for 
hematological malignancies. MethOds: An observational study was conducted at a 
public Canadian acute care clinical laboratory in collaboration with a lean specialist 
team for the purposes of workflow analysis. The results of this pilot were used to 
inform this extended costing analysis. Evaluation of the instrument, reagent, and 
sample preparation was performed. Total opportunities for error in the workflow 
were identified (defined as steps involving manual efforts) and manual labor time 
was then used to estimate indirect costs. Results: A total of 37 steps were involved 
in instrument set-up, 81 steps for manual reagent and sample preparation, each 
of these steps containing multiple opportunities for error. At a 550 bed institution 
performing 591 leukemia and lymphoma tests annually, it was estimated that a 
total of 365 hours of manual labor by a skilled medical lab technologist incurred 
indirect costs of $18,250. cOnclusiOns: Based on this case study, manual work 
resulted in substantial cost to the laboratory in indirect costs. This suggests that 
in addition to reducing the potential for error, minimizing unnecessary manual 
steps in the flow cytometry workflow could also reduce laboratory indirect costs 
and improve efficiency. Future research is warranted to quantify the frequency of 
errors in manual steps in LDT for flow cytometry.
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Objectives: Human epidermal growth factor receptor 2 (HER2) status identifi-
cation is established by immunohistochemistry and in situ hybridisation (ISH). 
Silver in situ hybridisation (SISH) is an alternative technique to the fluorescence in 
situ hybridization (FISH). Both methods are recommended by American Society of 
Clinical Oncology (ASCO)/College of American Pathologists (CAP) 2013 guidelines. 
The primary aim of this analysis is to evaluate the economical and organizational 
impact by adopting FISH or SISH test for HER2 testing. MethOds: We conducted 
an analysis to evaluate costs, times (laboratory personnel working hours) and 
laboratory-space to process a sample using the manual method (FISH) compared 
to the automated system (SISH). The analysis was performed from the pathology 
laboratory’s perspective. We analysed the complete workflow (laboratory personnel 
and medical resource used) to perform the two tests (FISH and SISH) during pathol-
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Objectives: The majority of patients who get an implantable cardioverter defi-
brillator (ICD) for primary prevention of sudden cardiac death (SCD) never need to 
receive appropriate ICD therapies. Better risk-stratifying tools are thus needed to 
improve the cost-effectiveness of device implantation. The purpose of this study 
was to assess the cost-effectiveness of using delayed enhancement cardiac mag-
netic resonance (CMR) to refine patient selection for ICD therapy in primary pre-
vention. MethOds: A Markov model was developed to assess long-term survival, 
quality-adjusted life years (QALYs), and lifetime costs for a cohort of patients with 
reduced left ventricular ejection fraction without previous ventricular arrhythmias. 
Two different strategies were compared: A) implant an ICD in all patients (“ICD for 
all”); and B) perform CMR and implant an ICD only in patients with delayed enhance-
ment exceeding 5% of myocardial mass (“CMR-guided ICD”). Clinical and economic 
inputs were derived from European representative literature. Results: The “ICD 
for all” strategy led to a total cost of 68,818€ and 7.0 QALY per patient, implying an 
incremental cost of 7,372€ and allowing a gain of 0.1 QALY when compared to the 
strategy “CMR-guided ICD”. Consequently, the cost-utility ratio is 77,943€ per QALY. 
Probabilistic sensitivity analysis showed that, assuming a willingness to pay of 
50,000€ per QALY, the “ICD for all” strategy would be cost-effective in 31 % of the sim-
ulations. cOnclusiOns: Results suggest that implanting ICD in selected patients 
allows to use this device in those that benefit most, improving the cost-effectiveness 
of ICD implantation for the primary prevention of sudden cardiac death.
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Objectives: Mutations in BRCA1 and BRCA2 genes are associated with an increased 
risk of breast and ovarian cancer. If a BRCA mutation is detected in women with 
ovarian cancer their unaffected relatives may be offered genetic testing and pro-
phylactic surgery. The long-term cost-effectiveness of providing BRCA testing to 
women with ovarian cancer and to their unaffected female first-degree relatives 
in the UK has previously been evaluated using a lifetime Markov model, but the 
approach had a number of limitations. The current study will employ a hybrid dis-
crete event simulation (DES) structure that addresses some of the Markovian limi-
tations associated with the previous model and will differentiate between BRCA1 
and BRCA2 mutations and will consider results for a number of possible UK family 
pedigrees. MethOds: A hybrid DES will be constructed with a lifetime horizon, 
to evaluate the cost-effectiveness of BRCA testing in women with ovarian cancer 
and their female first- and second-degree relatives versus no testing. The model 
will consider the incidence of ovarian and breast cancer, differentiating between 
those with BRCA1 and BRCA2 mutations, as well as the associated mortality rates. 
Individuals identified as BRCA1 or BRCA2 positive will be eligible to undergo bilat-
eral mastectomy and bilateral salpingo-oophorectomy, which significantly reduce 
the risk of both ovarian and breast cancer. Results: Results will be presented as 
an incremental cost-effectiveness ratio expressed as a cost per quality adjusted 
life year (QALY). These will be compared to the UK cost-effectiveness threshold of 
£20,000 per QALY gained. A number of sensitivity and subgroup analyses will be 
presented alongside the base case. cOnclusiOns: We aim to demonstrate that 
screening patients with ovarian cancer and their first- and second-degree relatives 
for the BRCA1 and BRCA2 mutation is cost-effective and reduces the incidence of 
breast and ovarian cancer in the population.
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Objectives: To develop an economic model to inform recommendations on the 
optimal diagnostic pathway for the recent clinical guideline on the diagnosis and 
monitoring of asthma, commissioned by the National Institute for Health and Care 
Excellence (NICE). MethOds: A de-novo economic model evaluated current prac-
tice alongside six diagnostic pathways comprising of the following tests: spirometry, 
bronchodilator reversibility (BDR), peak expiratory flow (PEF), fractional exhaled 
nitric oxide (FeNO) and methacholine/histamine challenge testing (MCT). A model 
was developed using a decision tree to identify what proportion of individuals would 
receive a correct (true positive, true negative) or incorrect (false positive, false nega-
tive) diagnosis, utilising diagnostic accuracy data in adults from systematic reviews 
conducted for each test. These proportions fed into one of four Markov models, 
depending on the diagnosis, which calculated final health and cost outcomes. The 
model explored the impact of alternative false diagnoses, such as chronic obstruc-
tive pulmonary disease, and applied modelling techniques to account for the effect 
of conditional dependence on diagnostic accuracies. Results: The most cost-effec-
tive strategy at a £20,000 per/QALY threshold consisted of all individuals undergoing 
